Bone Biologics Corporation
$1.38
▲
6.9%
2026-04-21 05:34:01
www.bonebiologics.com
NCM: BBLG
Explore Bone Biologics Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.5 M
Current Price
$1.38
52W High / Low
$6.75 / $1.05
Stock P/E
—
Book Value
$3
Dividend Yield
—
ROCE
-60.16%
ROE
-70.17%
Face Value
—
EPS
$-2.65
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
0.37
Debt / Equity
—
Current Ratio
13.85
Quick Ratio
13.85
Forward P/E
-0.78
Price / Sales
—
Enterprise Value
$-3.07 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$22.2
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 2. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
| 3. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 4. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
| 5. | Acurx Pharmaceuticals, Inc. | $2.36 | — | $6.79 M | — | -153.59% | -2.71% | $21 / $1.33 | $2.24 |
| 6. | Alnylam Pharmaceuticals, Inc. | $310.49 | 133.51 | $41.46 B | — | 14.33% | 73.28% | $495.55 / $228.28 | $5.96 |
| 7. | Savara Inc. | $5.61 | — | $1.15 B | — | -52.68% | -63.45% | $7 / $1.89 | $0.8 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.73 M | -0.72 M | -0.75 M | -1.04 M | -1.55 M | — |
| Net Profit | -0.68 M | -0.67 M | -0.74 M | -1.02 M | -1.52 M | — |
| EPS in Rs | -0.38 | -0.37 | -0.41 | -0.57 | -0.85 | -14.21 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -3.23 M | -4.22 M | -9.43 M | -3.67 M |
| Net Profit | -3.11 M | -4.11 M | -8.95 M | -1.48 M |
| EPS in Rs | -1.73 | -2.29 | -4.98 | -0.83 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.8 M | 3.86 M | 3.74 M | 8.5 M |
| Total Liabilities | 0.42 M | 0.38 M | 0.83 M | 2.55 M |
| Equity | 5.38 M | 3.48 M | 2.91 M | 5.95 M |
| Current Assets | 5.8 M | 3.86 M | 3.74 M | 8.5 M |
| Current Liabilities | 0.42 M | 0.38 M | 0.83 M | 2.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.69 M | -4.12 M | -9.56 M | -3.57 M |
| Investing CF | — | — | — | — |
| Financing CF | 4.7 M | 4.42 M | 5.04 M | 4.43 M |
| Free CF | -2.69 M | -4.12 M | -9.56 M | -3.57 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 54.04% | -502.76% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-10 | 1:0.166667 |
| 2023-12-20 | 1:0.125 |
| 2023-06-07 | 1:0.0333333 |